MEA Prostate Cancer Market

MEA Prostate Cancer Market Size (2023 to 2028)

The prostate cancer market size in the Middle East & Africa is estimated to grow from USD 5.5 billion in 2023 to USD 8.61 billion by 2028, growing at a CAGR of 9.38% from 2023 to 2028.

Prostate cancer is the abnormal and uncontrolled growth of cells in the prostate gland of a male individual. The majority of prostate cancers are developed sporadically in which genetic changes occur after birth. Although the cause of prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. In addition, a person with cardiovascular disease is more prone to advanced metastatic cancer.

Promising drug pipelines, developing treatment patterns, rising untapped non-metastatic prostate cancer space, and increased patient awareness are the factors that are expected to enhance the market growth. In addition, improved government funding for cancer and growing awareness about prostate cancer would be one of prime reasons for the unparalleled market growth.

Stringent regulations are restraining the growth of the prostate cancer market in the MEA region.

This research report on the Middle East and Africa prostate cancer market has been segmented and sub-segmented into the following categories.

By Diagnostic Techniques: 

• Digital Rectal Exam (DRE)
• Prostate-Specific Antigen Test (PSA)

By Surgery: 

• Radical Prostatectomy
• Orchidectomy
• Trans Urethral Resection (TUR)

By Radiation Therapy: 

• External Beam Radiation Therapy
• Brachytherapy

By Chemotherapy: 

• Docetaxel
• Etoposide
• Vinblastine
• Carboplatin
• Vinorelbine

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the South African prostate cancer market is predicted to account for the largest share among others in the MEA region during the forecast period, owing to a growing focus on prostate cancer diagnostics products and increased awareness of the disease. In addition, prostate cancer growth is closely linked to age, and with the growing geriatric population, there is a significant increase in prostate cancer incidence. This is projected to drive the prostate cancer diagnostics market by increasing the demand for diagnostics products to detect the condition.

During the forecast period, technological developments in diagnostic tests are expected to boost MEA market expansion further. According to the National Cancer Institute, researchers are now studying the use of artificial intelligence to identify prostate cancer. During a Magnetic Resonance Imaging scan, AI technologies identify problem spots that require biopsies to validate the diagnosis. It is the second leading cause of cancer morbidity and mortality among Ethiopian men. Despite a few studies on the disease burden, evidence on prostate cancer patients' survival and prognostic variables in Ethiopia is limited. As a result, the survival and predictive variables of individuals with prostate cancer were explored in this research. With the increase in new market players aiming to enter into the business through distribution agreements and investing in prostate cancer diagnosis, the sector is expected to expand, creating an opportunity for the prostate cancer diagnostics market.

KEY MARKET PLAYERS:

Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech are some of the notable companies in the MEA prostate cancer market.